Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arhalofenate - CymaBay Therapeutics

Drug Profile

Arhalofenate - CymaBay Therapeutics

Alternative Names: JNJ 39659100; K-118; MBX-102; Metaglidasen

Latest Information Update: 12 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabolex
  • Developer CymaBay Therapeutics
  • Class Amides; Anti-inflammatories; Antigouts; Antihyperglycaemics; Insulin sensitisers; Small molecules; Uricosurics
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gout; Type 2 diabetes mellitus

Most Recent Events

  • 12 Jul 2019 Discontinued - Phase-II for Gout (Combination therapy) in Canada, Georgia, USA (PO) (Cymabay Therapeutics pipeline, July 2019)
  • 12 Jul 2019 Discontinued - Phase-II for Gout (Monotherapy) in Canada, Georgia, USA (PO) (Cymabay Therapeutics pipeline, July 2019)
  • 30 Oct 2018 Kowa Pharmaceuticals terminates its licence agreement for the treatment of Gout in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top